General Information of DTT (ID: TT1D53B)

DTT Name COVID-19 3C-like protease (3CLpro) DTT Info
Gene Name COVID-19 rep

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Preclinical Drug(s)
Clinical Trial Drug(s)
Approved Drug(s)
1 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
BOCEPREVIR DMBSHMF Hepatitis C virus infection 1E51.1 Approved [1]
------------------------------------------------------------------------------------
1 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-07817883 DMNX86H Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1 [2]
------------------------------------------------------------------------------------
1 Preclinical Drugs Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
GC376 DMR1CLY Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [1]
------------------------------------------------------------------------------------
1 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
GRL001 DM19T2V Coronavirus infection 1D92 Preclinical [3]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. 2020. April 20. doi: https://doi.org/10.1101/2020.04.20.051581
2 ClinicalTrials.gov (NCT05580003) COVID-19: A MULTIPART, PHASE 1 STUDY WITH RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE-DOSE ESCALATION TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-07817883 AND OPTIONAL OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE RELATIVE BIOAVAILABILITY AND FOOD EFFECT OF SOLID ORAL FORMULATION AND OPTIONAL OPEN-LABEL, NON-RANDOMIZED STUDY TO EVALUATE METABOLISM AND EXCRETION OF PF-07817883 AND OPTIONAL RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE EFFECT OF PF-07817883 ON PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY ADULT PARTICIPANTS. U.S.National Institutes of Health.
3 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.